| 51 |
30617528 | [Systemic treatment of metastatic tumors of the upper urinary tract]. | 2019 Jan |
1 |
| 52 |
30666091 | Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. | 2019 |
1 |
| 53 |
30741358 | Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. | 2019 Feb 11 |
1 |
| 54 |
30851984 | The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. | 2019 Jun |
1 |
| 55 |
30952714 | Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. | 2019 Apr |
2 |
| 56 |
30961670 | Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. | 2019 Apr 8 |
3 |
| 57 |
31105696 | Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. | 2019 |
2 |
| 58 |
31173242 | Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer. | 2019 Aug |
2 |
| 59 |
31186170 | Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. | 2019 Sep |
5 |
| 60 |
31267201 | Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. | 2019 Nov |
1 |
| 61 |
31289485 | Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. | 2019 Jul |
2 |
| 62 |
31341011 | Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. | 2019 Sep 30 |
6 |
| 63 |
31366557 | Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. | 2019 Aug |
1 |
| 64 |
31404614 | Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. | 2019 Nov 1 |
7 |
| 65 |
31495720 | Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. | 2019 Sep |
2 |
| 66 |
31864288 | Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. | 2019 Dec 21 |
1 |
| 67 |
29306075 | FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells. | 2018 Mar |
4 |
| 68 |
29325739 | Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. | 2018 Apr |
4 |
| 69 |
29361135 | Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. | 2018 Jan 1 |
1 |
| 70 |
29606979 | PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. | 2018 |
1 |
| 71 |
29644490 | Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. | 2018 Apr 11 |
1 |
| 72 |
29675791 | Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. | 2018 Jul |
1 |
| 73 |
29761938 | Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. | 2018 May 15 |
4 |
| 74 |
29855698 | Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. | 2018 Nov |
1 |
| 75 |
29960831 | Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. | 2018 Oct |
1 |
| 76 |
30603685 | Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. | 2018 Dec |
2 |
| 77 |
27864219 | Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). | 2017 Mar 1 |
3 |
| 78 |
28801607 | Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. | 2017 Aug 11 |
2 |
| 79 |
28819582 | Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. | 2017 Jun |
3 |
| 80 |
28994323 | Atezolizumab in invasive and metastatic urothelial carcinoma. | 2017 Dec |
2 |
| 81 |
29031195 | Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. | 2017 Dec |
1 |
| 82 |
29228662 | Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. | 2017 Nov 17 |
4 |
| 83 |
27181838 | PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. | 2016 May 16 |
2 |
| 84 |
27581532 | Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. | 2016 Nov |
5 |
| 85 |
27610620 | Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. | 2016 |
4 |